You just read:

Kymera Therapeutics to Present Preclinical Data on its First-in-Class Selective and Potent Oral IRAK4 Degraders in Cutaneous Inflammation

News provided by

Kymera Therapeutics Inc.

Feb 05, 2020, 08:00 ET